AIM ImmunoTech highlights recent key financial milestones

AIM ImmunoTech (AIM) highlighted recent key financial milestones and firmly stated its focus on advancing clinical trials of Ampligen for the treatment of pancreatic cancer, with the ultimate goal of achieving drug approval. Significant Achievements: Resumed trading on the NYSE American; Closed public equity offering, raising $8.0 million in gross proceeds, which is expected to fund operations for approximately 12 months; Reported positive data in a mid-year update from the ongoing Phase 2 clinical study evaluating AIM’s drug Ampligen combined with AstraZeneca’s (AZN) anti-PD-L1 immune checkpoint inhibitor Imfinzi in the treatment of metastatic pancreatic cancer patients with stable disease post-FOLFIRINOX; Granted U.S. patent covering methods of manufacturing therapeutic dsRNA, including Ampligen; Granted U.S. patent for Ampligen in combination with PD-L1 drugs for the treatment of cancer; Granted U.S. and EU Orphan Drug designations for pancreatic cancer; Ampligen oncology data presented at scientific congresses including the Annual Meeting of the American Association of Immunologists and U.S.-Poland Science and Technology Symposium 2025